Clinicopathological analysis of non-functioning pituitary adenomas (PAs) according to the 2022 WHO classification
Authors' conclusion
Our findings indicate that patients with high-risk NFPAs have a more aggressive disease course and a higher rate of progression or recurrence. This high-risk group has higher prevalence of younger and female patients. They may benefit from closer monitoring and possibly more aggressive treatment approaches.
Study context
- Population
- Patients with non-functioning pituitary adenomas (NFPAs) who underwent surgery between November 2017 and December 2022 at one institution
- Participants
- 125 patients
- Exposure
- High-risk vs low-risk NFPAs
- Outcome
- Tumor progression or recurrence
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Tumor progression/recurrence
- High-risk group at diagnosis remained an independent prognostic factor in multivariate analysis
- p-value = 0.0148
Observational data: associations, not effects.
Further findings
Younger patients
P = 0.016
Female patients
P < 0.001
Cavernous sinus invasion and Ki-67 index
- Cavernous sinus invasion and higher Ki-67 index more common in High-risk, but did not significantly impact overall prognosis
Original publication
Clinicopathological analysis of non-functioning pituitary adenomas (PAs) according to the 2022 WHO classification. Pituitary. Published 19 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →